

LEADING THE WAY IN PHARMACEUTICAL GROWTH AND EXCELLENCE IN PAVIA

In Italy since 2005, the multinational Hikma celebrates its first 20 years in our country. We talked about it with general manager Roberto Gagliano **20 years**

The multinational company Hikma established a presence in Italy in 2005, drawing on the expertise of a local company specialising in freeze-drying. This complex technology serves Hikma's primary objective of producing and distributing high-quality medicines to those who need them. "We are proud to celebrate these first 20 years of Hikma Italia", says general manager Roberto Gagliano, "We can say that we have established ourselves as a key player in the production of injectable medicines, sold both on the domestic

and international markets". In particular, Hikma invested €36 million in its various production sites across Europe in 2024. Its focus on implementing the highest quality standards in the production and control of injectable medicines enables it to supply essential medicines to various national health systems, with the aim of making treatments more accessible to patients throughout Italy, Europe, and the rest of the world. "The ongoing investment in the Pavia production site reflects Hikma's commitment to developing the Italian pharmaceutical

industry and responding to patients who benefit from our medicines", adds Roberto Gagliano. "The company has already allocated resources to expand the production capacity of the Pavia site further and to improve warehouse efficiency. This structure and the continuity that Hikma has chosen to give to the investment demonstrate their long-term commitment to Italy, and their confidence in this country as a major player in the international pharmaceutical context". The Italian site employs 140



The management of Hikma Italy

The Italian site employs 140 people including scientists, production staff, quality experts and of course support staff



GOAL: BETTER HEALTH FOR ALL

Hikma Italia is the Italian subsidiary of Hikma, a pharmaceutical company listed on the London Stock Exchange and active in North America, the Middle East and North Africa (Mena) and Europe as a producer and supplier of generic, branded, and speciality pharmaceuticals. Thanks to high-quality products that it makes accessible to those who need them, it contributes every day to the goal of better health. There are 262 million patients treated globally. In 2024, it invested \$165 million to improve and expand its production capacity (source: <https://www.hikma.com/investors/recent-results/>, 5 August 2025).

people including scientists, production staff, quality experts and of course support staff. "We firmly believe that investing in people is just as important as investing in production facilities", says the manager. "That's why we have established a solid partnership with the University of Pavia. The collaboration allows students and graduates to get real work experience in an international pharmaceutical company like Hikma, working in the context of production, quality assurance, quality control and support functions".

The available internships are aimed at both undergraduate and graduate students, bridging the gap between academic study and industrial applications. Moreover, most of these stages result in the permanent entry of an exciting new talent into the Hikma team. The collaboration also developed with Roberto Gagliano's teaching in several Master's courses at the University of Pavia. An exchange that benefits both sides, enhancing local talent and providing Hikma with a pool of trained professionals. Hikma's local investment in the Pavia plant is therefore crucial for the entire region.

"In addition to Hikma's direct employees", Roberto Gagliano continues, "the company

is creating an innovative industrial environment that supports local suppliers and positions Hikma Italia as a leader in the pharmaceutical context. By nurturing local scientific talent, we are helping to ensure that Italy remains competitive within the global pharmaceutical industry and that patients always have access to high-quality medicines".

Hikma thus also brings to our country the high quality standards it has chosen to set for itself in the production of drugs, their control, pharmacovigilance and the continuous improvement of all processes, with strict adherence to international good manufacturing practice, local regulatory requirements and contractual agreements at heart.

